• In the GDG' s assessmen t, only a minority o f low-risk patients will choose t o consider using nirmatr elvir-ritonavir.
• Trials on antivirals included patien ts with some risk f actors for hospital admission, resulting in a baseline risk o f 3% that the GDG applied to generate the r ecommendation. T he risk of hospitalization is likely to be lo wer in the g eneral population.
• Clinicians should no t consider nirmatrelvir-ritonavir in patien ts with possible dang erous drug in teractions (note: man y drugs interact with nirmatr elvir-ritonavir).
• Fully informed shared decision-making should det ermine whether nirmatr elvir-ritonavir should be used in pr egnant or breastfeeding w omen, c onsidering possible benefits and unc ertainty regarding potential undesirable effects.

Practical Info Route, dosage and duration: Additional considerations are available in three summaries of practical issues (nirmatrelvir-ritonavir for COVID-19, administration of nirmatrelvir-ritonavir for COVID-19, safety and monitoring f or patients receiving nirmatrelvirritonavir for COVID-19). In any patient being c onsidered for nirmatrelvir-ritonavir use, clinicians need to giv e serious consideration to drug in teractions. The Liverpool COVID-19 drug interaction checker may be use ful in this regard (19).

Resources and other considerations Nirmatrelvir-ritonavir is unlikely to be a vailable for all individuals who, giv en the op tion, would choose to r eceive the treatment. This reinforces that nirmatrelvir-ritonavir be reserved for those at highest risk.